ArticleMolecules (Basel, Switzerland)2026
Dual-Stimuli Responsive Cystamine-Modified Polydopamine Coatings as Payload Gatekeepers.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
We present cystamine-modified polydopamine (PDA) coatings as tunable gatekeepers for mesoporous silica nanoparticles (MSNs) in drug delivery. Unlike conventional post-functionalization strategies, cystamine moieties were incorporated directly into the PDA network, enabling tunable shell composition and redox responsiveness by simply adjusting the dopamine-to-cystamine ratio. By varying the cystamine:dopamine ratio, pH- and redox-responsive release of doxorubicin (DOX) and sorafenib (SO) was achieved, with release kinetics following the Higuchi model. Cystamine-modified PDA nanoparticles with varying disulfide bridge content were synthesized and comprehensively characterized using SEM, TGA, FTIR, and zeta potential measurements. The cystamine content was found to influence thermal stability, coating performance, and protective properties. Importantly, increasing disulfide content did not necessarily improve release performance, suggesting that excessive crosslinking may partially restrict shell permeabilization and drug diffusion. These findings reveal important structure-property relationships in catechol-based coatings and underline the significance of disulfide linkages in the design of bioinspired stimuli-responsive drug delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.